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Abstract
Background/Aim. Thermodynamical and cryobiological pa-
rameters responsible for cell damages during cryopreservation
(cryoinjuries) have not yet been completely explained. Thus,
freezing procedures should be revised, exactly optimized to
obtain an enhanced structural and functional recovery of fro-
zen–thawed cells. The aim of this study was to compare mic-
roprocessor–controlled (controlled–rate) with the compensati-
on of the released fusion heat and “dump–freezing” (uncon-
trolled–rate) of the platelet and lymphocyte cryopreservation
efficacy.  Methods.  Platelet quantitative recovery (post–thaw
vs. unfrozen cell count), viability (using hypotonic shock res-
ponse – HSR), morphological score (PMS), ultrastructural
(electron microscopy) properties and expression of different
surface antigens were investigated. In lymphocyte setting, cell
recovery and viability (using trypan blue exclusion test) as well
as functionality (by plant mitogens) were determined. Control-
led–rate freezing and uncontrolled–rate cryopreservation were
combined with 6% (platelets) and 10% (lymphocytes) dimethyl
sulfoxide (DMSO). Results. Platelet recovery and functionality
were superior in the controlled–rate system. The majority of
surface antigen expression was reduced in both freezing groups
vs. unfrozen cells, but GP140/CD62p was significantly higher
in controlled–rate vs. uncontrolled–rate setting. Controlled–
rate freezing resulted with better lymphocyte recovery and
viability (trypan blue–negative cell percentage). In mitogen–in-
duced lymphocyte proliferative response no significant inter-
group difference (controlled–rate vs. uncontrolled–rate) were
found. Conclusion. The data obtained in this study showned
the dependence of cell response on the cryopreservation type.
Controlled–rate freezing provided a superior platelet quantitative
and functional recovery. Lymphocyte recovery and viability were
better in the controlled–rate group, although only a minor inter-
group difference for cell proliferative response was obtained.
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Abstrakt
Uvod/Cilj. Termodinamski i kriobiološki parametri, odgovorni za
oštećenje  ćelija do kojih dolazi tokom kriokonzervacije (krio-
oštećenja), još uvek nisu sasvim razjašnjeni. Stoga, postupke zamrz-
vanja treba tako optimizirati da se poboljša i strukturni i funkcionalni
oporavak zamrznuto-razmrznutnih ćelija. Cilj ove studije bio je upo-
ređivanje efikasnosti kriokonzervacije trombocita i limfocita prime-
nom programirane kriokonzervacije (mikroprocesorom kontrolisana
brzina hlađenja), uz kompenzaciju oslobođene toplote fuzije, i nep-
rogramirane kriokonzervacije (bez kompjuterske kontrole brzine
hlađenja). Metode. Istraživali smo kvantitativni oporavak trombo-
cita (broj ćelija posle odmrzavanja nasuporot broju ćelija pre zamrza-
vanja), vijabilnost (koristeći reakciju trombocita na hipotoni šok –
HAR), morfološki skor trombocita (PMS), ultrastrukturne (elektro-
mikroskopski) karakteristike i ekspresiju različitih površinskih antige-
na. Kod limfocita odredili smo njihov kvantitativni oporavak i vija-
bilnost (primenom testa isključivanja tripan plavog), kao i funkcio-
nalnost (stimulacijom pomoću mitogena). Programirana i neprogra-
mirana kriokonzervacija su kombinovane sa 6% (trombociti) i 10%
(limfociti) dimetil-sulfidom (DMSO). Rezultati. Oporavak trombo-
cita bio je bolji pri uslovima kontrolisane brzine. Većina ekspresije
površinskih antigena snižena je bila u obe ispitivane grupe u odnosu
na nezamrznute ćelije, dok je ekspresija GP140/CD62p bila znatno
veća pri uslovima programirane u odnosu na neprogramiranu krio-
konzervaciju. Programirana kriokonzervacija je rezultovala boljim
oporavkom i vijabilnošću limfocita (procenat tripan plavo – negativ-
nih ćelija). Nismo utvrdili značajnu razliku među grupama (progra-
mirana vs neprogramirana kriokonzervacija) u proliferativnoj reakciji
limfocita prilikom ispitivanja reakcije limfocita nakon indukcije mito-
genom. Zaključak. Podaci dobijeni u ovoj studiji pokazali su zavis-
nost oporavka ćelija od vrste kriokonzervacije. Zamrzavanje pri
kontrolisanoj brzini omogućilo je bolji kvantitativni i funkcionalni
oporavak trombocita. Oporavak i vijabilnost limfocita bili su bolji u
grupi sa programiranom kriokonzervacijom, mada je konstatovana
mala razlika u proliferativnoj reakciji ćelija među grupama.
Ključne reči:
kriokonzervacija; trombociti; limfociti;
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Introduction
Current increasing use of different cell–mediated thera-
peutic approaches has resulted in increasing needs for both
blood cells and operating procedures in order to minimize
cell damages during their collection, processing and storage
in liquid or frozen state. Freezing of isolated cells by various
cryopreservation systems has been investigated for many
years as a method of long–term storage at cryogenic (sub-
zero) temperatures. Current freezing techniques are devel-
oped from the initial report of the cryopreservation of bovine
sperm 
1. Cryothermal damages (cryoinjuries) may be the re-
sult of extensive cell dehydration (“solution effect”) or intra-
cellular ice crystallization (“mechanical damage”) and they
result in cell destruction 
2–8. Different freezing procedures
(modifications of the Polge–Smith–Parkers method) are in
routine use for hematopoietic stem cell and progenitor, as
well as mature blood cell cryopreservation. The ability of
human stem cells to survive a freezing–thawing procedure
results in marrow repopulation and hematopoietic reconsti-
tution after transplantation 
9–21. Nowadays numerous freezing
techniques are used in the practice of platelet 
22–31 and lym-
phocyte 
32–36 cryopreservation. However, the optimal cryo-
preservation strategy with the greatest quantitative and
qualitative cell recovery is still unsolved.
In this study, the influence of the different cryopreserva-
tion approaches on the platelet and lymphocyte quantitative
and functional recover was compared. It is proposed that the
use of controlled–rate vs. uncontrolled–rate (“dump–freezing”)
procedure will provide a superior cell recovery. Cryopreserva-
tion was carried out using our own controlled–rate systems
designated for lymphocyte and platelet cryopreservation, as
well as by a standard "dump–freezing" technique under opti-
mized dymethyl sulfoxide (DMSO) conditions.
Methods
Platelet and lymphocyte collection and testing
The study included 70 whole blood units collected
into CPD SAGM plastic bags (Terumo, Japan), designated
for platelet (n  =  35) or lymphocyte (n  =  35) harvest. The
primary buffy–coat (BC–I) was obtained by centrifugation
(3 890 × g for 10 min) (Hettich, Germany) and processing
of whole blood (450±45  ml) collected from donors in
steady–state hematopoiesis into a quadruple bag system
(Terumo, Japan). Secondary buffy–coat (BC–II) and buffy–
coat derived platelet concentrates (BC–PC) was prepared
by centrifugation (377 × g for 5 min) and processing from
BC–I 
12, 28. Lymphocytes were isolated from BC–II by cen-
trifugation (320 × g for 35 min) using Ficoll–Paque (Phar-
macia Fine Chemicals, Sweden) as a gradient agent. BC–
PC samples (2 ml) were dropped by an automatic micropi-
pette into thermo–stable plastic tubes for testing (control
group) or cryopreservation. Lymphocytes resuspended in
RPMI 1640 culture medium (Serva Feinbiochemica, USA)
were taken in the same quantities (2 ml) into plastic tubes
for in vitro investigations (control group) or cryopreserva-
tion 
28, 31, 34.
Platelet count was determined by flow cytometry
(Technicon, USA). Platelet morphology was examined by a
phase–contrast microscope (Polyvar, Austria) 
31. The PMS
was calculated according to the numerical values (bal-
loons = 0; dendrites = 1; spheres = 2; discs = 4) of different
platelet shapes 
28, 29. The platelet viability was assessed ac-
cording to their hypotonic shock response (HSR) as de-
scribed earlier 
31, 32. Platelet ultrastructure was examined us-
ing an electron microscope (Philips, The Netherlands).
Platelet surface antigens (GPIb/CD42b, GPIIb–IIIa/CD41,
GP140/CD62p, GP53/CD63, and GPIX/CD42a) were ex-
amined using specific monoclonal antibodies (CLB, The
Netherlands), while afterward cells were analyzed by an Ep-
ics XL (Coulter, USA) 
25.
Lymphocyte count in the unfrozen (control) and fro-
zen/thawed samples was quantified manually by a Neubauer
chamber. Cell viability was investigated by the trypan blue
exclusion test. Based on the quantity and viability of thawed
lymphocytes, post–cryopreservation total trypan blue–nega-
tive lymphocyte recovery (TBNCR) was determined. To as-
sess functional statement of cryopreserved lymphocytes 0.5 ×
10
6 cells were cultivated with different concentration of plant
mitogens, phytohemaglutinin (PHA) (Sigma, USA) and con-
canavalin–A (Con–A) (Sigma, USA), in complete RPMI 1640
culture medium in 96–well microplates (Flow, Irvine, UK).
Within the last 18 h cells were pulsed with 
3H–thymidine
(1 μCi/well) (Amersham, UK). Radioactivity was determined
on a beta scintillation counter (Beckman, Germany). Data are
expressed as counts per minute (CPM) ± SE and the stimula-
tion index (SI) 
33–37.
Cell cryopreservation
Cell samples (2 ml) were placed into plastic tubes for
cryopreservation. Then, an equal volume (2 ml) of DMSO
(Sigma, USA), diluted in autologous plasma (platelet setting)
or RPMI 1640 culture medium (lymphocyte setting) was
added to cell suspensions. DMSO in 6% (for platelets) and
10% final concentration (for lymphocytes) with both con-
trolled–rate and uncontrolled–rate freezing were combined.
Thus, four cryopreservation protocols: platelet and lympho-
cyte controlled–rate (Con−Plt and Con−Ly) and uncon-
trolled–rate (Unc−Plt and Unc−Lymphocyte) were investi-
gated.
The uncontrolled–rate freezing without the balanced
cooling rate (around 1–2  °C/min) was performed after the
equilibration period by simple placing of the
cell/cryoprotectant suspension into a mechanical freezer at –
90±5 °C 
19–21. Our own controlled–rate procedures for plate-
lets 
28 and lymphocytes 
12 were accomplished by a Planer
R203/200R and Planer 560–16 (Planer Products Ltd, Eng-
land) with the equalized (1  °C/min) cooling velocity. The
platelet controlled–rate freezing procedure consists of the
following stages: I = -5 °C/min, to 0 °C; II = 0 °C/min, for 5
min (equilibration); III  =  -1  °C/min, for 5 min; IV  =  -
2 °C/min, for 5 min; V = -1 °C/min, for 30 min and VI = -
5 °C/min, for 5 min. The controlled–rate lymphocyte freezing
method consisted of the following stages: I = -5° C/min, to 0° C;
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min; IV = -1 °C/min, for 35 min and V = -5 °C, for 5 min. Dur-
ing the phase transition period (liquid to solid state) from –
5  °C to –15  °C (platelet setting) and from 0  °C to –10  °C
(lymphocyte setting) an intensified (double over) cooling
rate (2 °C/min) was used due to the compensation of the re-
leased fusion heat 
10, 28.
After the completion of controlled–rate freezing proce-
dures, cells were placed into a mechanical freezer (Eurospi-
tal, Italy) at the temperature of -90±5 °C till thawing (one to
tree months) and the structural and functional investigations
that followed. The frozen cell samples were thawed rapidly
in a water bath at 37±3 °C.
Statistical analysis
The results were expressed as a mean value ± standard
deviation (SD) or mean value ± standard error (SE). Prolif-
erative response of lymphocytes after controlled–rate vs. un-
controlled–rate freezing was compared by the General Linear
Model method and Paired Samples t–test. The results ob-
tained before and after freezing of platelets were compared
by Student's t–test, using the Original PC Program. The dif-
ferences were considered as significant at p < 0.05.
Results
The results related to platelet and lymphocyte recovery
and viability obtained in this study are presented in Table 1.
The intergroup (controlled–rate vs. uncontrolled–rate)
differences showed that there was better platelet and lym-
phocyte quantitative recovery (p < 0.05) in the controlled–
rate groups.  Uncontrolled–rate freezing caused higher
platelet HSR reduction with the significant intergroup
differences (p < 0.01). Regarding cell viability, there were no
significant differences neither between the cryopreserved vs.
control group, nor between lymphocytes frozen by both
freezing methods. On the contrary, the TBNCR values for
lymphocytes were significantly (p  <  0.05) higher in the
controlled–rate setting.
The PMS values were rapidly reduced after cryopreser-
vation, regardless the applied procedure. For controlled–rate
cryopreserved platelets, PMS was 81.8±2.8  %, while for
those frozen by the uncontrolled–rate technique PMS was
75.7±3.9 % (Table 2).
The analysis of PMS recovery confirmed that the inter-
group differences were significant (p < 0.05) in favor of the
controlled–rate freezing.
The results of platelet surface marker investigations be-
fore and after cryopreservation are presented in Table 3.
GPIb/CD42b expression was reduced, in both freezing
groups as compared to the control one, with no significant
intergroup (controlled–rate vs. uncontrolled–rate) differ-
ences. On the contrary, noticable intergroup differences
(p < 0.05) for GP140/CD62p expression were observed, sug-
gesting that controlled–rate freezing provided lower platelet
activation.
GP53/CD63 showed an increased expression as com-
pared to the control group, but with no significant intergroup
Table 1
The recovery and viability of the frozen/thawed cells
Platelets Lymphocytes
Pltrecovery PltVB Lyrecovery LyVB LyTBNCR
Con−Plt* 91.0±5.5
† 68.0±23.2
‡ // /
Con−Ly* // 89.7±5.2
† 91.6±1.3 82.5±4.5
†
Unc−Plt* 86.0±6.5
† 51.6±17.5
‡ // /
Unc−Ly* / / 71.2±16.1
† 91.9±7.8 65.5±6.4
†
Data are expressed as mean ± SD;
*Protocols investigated: Con−Plt and Con−Ly = controlled–rate freezing with 6% and 10% DMSO;
Unc−Plt and Unc−Ly = uncontrolled–rate freezing with 6% and 10% DMSO;
Pltrecovery = cryopreserved/unfrozen (control) platelet count;
PltVB = calculated accordingly of the hypotonic shock response – HSR.
Lyrecovery = cryopreserved/unfrozen (control) lymphocyte count;
LyVB = lymphocyte viability (determined by trypan blue exclusion test);
TBNCR = post–cryopreservation total trypan blue–negative lymphocyte recovery;
† Intergroup (controlled–rate vs. uncontrolled–rate) differences (p < 0.05);
‡Intergroup (controlled–rate vs. uncontrolled–rate) differences (p < 0.01).
Table 2
Platelets morphological score values
Absolute PMS
Relative PMS
[%]
Control group 356.5±10.3 100
Con–Plt* 291.7±7.4
†‡ 81.8±2.8
†‡
Unc–Plt 269.9 ± 10.3
† 75.7±3.9
†
Data are expressed as mean ± SD;
*Protocols investigated: Con−Plt = controlled–rate freezing with 6% DMSO;
Unc−Plt = uncontrolled–rate freezing with 6% DMSO;
†Cryopreserved vs. unfrozen (control) (p < 0.01);
‡Intergroup (controlled–rate vs. uncontrolled–rate) differences (p < 0.05).Page 264 VOJNOSANITETSKI PREGLED Volumen 63, N
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differences. GPIIb–IIIa/CD41 values were lower than in the
control, but also without the significant intergroup differ-
ences.
Figure 1a shows the normal unfrozen discoid platelet
(control) with the typical ultrastructural properties. The elec-
tron microscopy appearance of platelets cryopreserved by
controlled–rate and uncontrolled–rate freezing are also pre-
sented in Figure 1b–e.
Fig. 1a – The ultrastructural (electron microscopy) prop-
erties of cryopreserved platelets
Unfrozen platelet.
Besides discoid and spheric shapes, there were several
dendritic platelets, in the controlled-rate freezing group (Fig-
ure 1b and 1c). The discoid platelets had maintained intact
microtubules and an open canalicular system with a minimal
damage of the membrane. Platelets frozen by the uncon-
trolled–rate procedure (Figures 1d and 1e) showed the mem-
brane damages and altered ultrastructural properties (den-
dritic or balloon shapes). In addition, these platelets regularly
had an unclear edge with numerous large pseudopodes.
Table 3
Surface antigen expression of cryopreserved platelets
CD markers Control Con−Plt* Unc−Plt*
GPIb/CD42b [%] 97.22 ±2 . 6  83.2   ±  3.6
† 86.08 ± 4.4†
GPIIb–IIIa/CD41 [%] 98.45 ± 0.6  97.47 ±  1.3 96.16 ±  0.8 ‡
GP140/CD62p [%]   8.88 ±  3.8  28.38 ±  5.2
† 34.91 ±  8.3†‡
GP53/CD63 [%]   0.79 ±  0.2    1.96 ±  0.9
†   2.08 ±  1.2†
*Protocols investigated:Con−Plt = controlled–rate freezing with 6% DMSO;
Unc−Plt = uncontrolled–rate freezing with 6% DMSO;
†Cryopreserved vs. unfrozen (control) (p < 0.05);
‡Intergroup (controlled–rate vs. uncontrolled–rate) differences (p < 0.05).
Fig. 1c – The ultrastructural (electron microscopy)
properties of cryopreserved platelets
Controlled–rate cryopreserved platelets.
Fig. 1d – The ultrastructural (electron microscopy)
properties of cryopreserved platelets
Uncontrolled–rate cryopreserved platelets.
Fig. 1b – The ultrastructural (electron microscopy)
properties of cryopreserved platelets
Controlled–rate cryopreserved platelets.Volumen 63, N
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Finally, Table 4 shows the mitogen (PHA and Con–A)
induced lymphocyte proliferative response in controlled–rate
and uncontrolled–rate setting.
The analysis of the obtained results of the lymphocyte
proliferative response demonstrated that the cryopreservation
resulted in no significant intergroup differences, regardless
the used freezing procedure.
Discussion
Our earlier cryoinvestigations 
10, 12, 28 pointed out the im-
portance of the kinetics of the programmed cooling for the to-
tal nucleated cell (TNC), lymphocyte and platelet cryopreser-
vation. In this study, we confirmed that the use of the con-
trolled–rate method had significantly influenced the protection
of quantity and functionality of frozen/thawed platelets. The
platelet postthaw recovery was exactly 91.0±5.5%, which was
better than in other studies (62 to 86%) reported 
22, 23, 37, 38.
The results obtained in this research showed that the
controlled–rate freezing yielded the improved platelet viabil-
ity, as projected across HSR. Although in this study the
lower HSR values were observed for both freezing proce-
dures (compared to the control one), the 32% reduction in
the controlled–rate setting is in accordance with other re-
ports. However, HSR value depends on some additional pa-
rameters, such as cell platelet age, cell membrane integrity,
type of platelet shapes, etc 
23, 31, 39. Finally, we believe that
HSR of cryopreserved platelets is not always a result of the
unsuccessful response of all cells, but could rather represent
an unequal response of different platelet shapes.
The examination of PMS also confirmed clearly that
controlled–rate freezing was more efficient than the uncon-
trolled–rate technique. Better PMS values obtained in the con-
trolled–rate setting were primarily due to a greater proportion
of platelets of disc shapes (around 70% in comparison with the
control). These data generally agree with those reported in the
literature on PMS values after freezing–thawing procedure. It
is generally accepted that the high–quality in vivo survival of
cells can be expected after transfusion if  50% or more of
platelets keep their disc shape after cryopreservation 
39–41.
The investigation of ultrastructural properties of platelets
confirmed the advantage of the controlled–rate freezing, since
it revealed that the discoid platelets cryopreserved by this
protocol had kept intact microtubules and an open canalicular
system, with the minimal membrane changes. The spheric
shaped platelets showed the lower electron density of cyto-
plasm, gradually changed the interior structure comparing to
other shapes, which was manifested by the marginal location
of granules and other cytoplasmatic organelles. This finding is
in accordance with our previous platelet cryoinvestigation 
28.
On the contrary, the samples cryopreserved by the uncon-
trolled–rate technique showed an abundance of the damaged
platelets and cell detritus, along with the lower percentage of
platelets with a partially protected membrane integrity. The
occurrence of the regular dendritic and balloon shapes, as well
as rare spheric platelets indicated reduced morphological
properties and the subsequent functionality of thawed cells.
Fig. 1e – The ultrastructural (electron microscopy)
properties of cryopreserved platelets
Uncontrolled–rate cryopreserved platelets.
Table 4
Mitogen–induced lymphocyte proliferative response
Controlled–rate freezing Uncontrolled–rate freezing
CPM
‡ SI
║ CPM
‡ SI
║
Unstimulated 1196 ±315 / 893±179 /
PHA I* 102404±16463 104±28 100638±13950 133±33
PHA II* 111939±14852 113±27 106173±13036 139±31
PHA III* 106167±11959 104±20 101005±10735 129±23
PHA IV* 101770±7513 98±14 99222±9859 124±18
Con–A I
† 6445±949 6±1 6569±628 8±1
Con–A II
† 65919±18102 66±24 58158±12681 79±26
Con–A III
† 102994±11449 103±22 96190±10064 128±31
Con–A IV
† 98755±11092 96±18 101698±7977 134±29
Data are expressed as mean ± SE; (four lymphocyte samples per each group);
‡CPM = counts per minute;
║SI = stimulation index;
*PHA concentrations used: I = 62.5 μg/ml;
II = 31.3 μg/ml;
III = 15.6 μg/ml;
IV = 7.8 μg/ml;
†Con–A concentrations used: I = 67.5 μg/ml;
II = 33.8 μg/ml;
III = 16.9 μg/ml;
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In the present study, GPIIb–IIIa/CD41 platelet surface
marker was investigated. In addition, platelet activation was
assessed by measuring the expression of GPIb/CD42b,
GP53/CD63 and GP140/CD62p (P–selectin). The last one is
expressed on the cell surface after the release from α–gran-
ules.
It is generally accepted that the cold–induced post–
transfusion platelet clearance with following compromised
clinical effectiveness should be mediated by GPIb/CD42b
reorganization into “clusters” 
42–47. Our preliminary cryoin-
vestigation (29) of cold–induced GPIb/CD42b alterations
was in agreement with these studies, particularly when un-
controlled–rate freezing was performed. We proposed that
the reduction of the GPIb/CD42b expression in the present
study (from 11.1 to 14.0%) might be partially caused by the
GPIbα/CD42b “relocation”. However, these values are
markedly better than those reported by Lozano (reduction >
50%) 
44. The mentioned “relocation” could probably make
surface antigens less accessible to monoclonal antibodies,
resulting in the obtained decrease of GPIb/CD42b expres-
sion the of cryopreserved vs. the control platelets. How-
ever, Hoffmeister et al. (personal communication) did not
find a reduced GPIbα/CD42b expression following cooling
using the monoclonal antibody for platelets, so they con-
cluded that clustering did not lead to “pseudo hyporeactiv-
ity”. In this context, GPIb/CD42b expression decrease
should be mediated by other mechanisms such as proteoly-
sis by plasmin, thrombin, neutrophil elastase or the activa-
tion of the cell “death machinery”, etc 
29, 46. The results
obtained in our study are comparable with those published
by Barnard et al., who also found a reduced GPIb/CD42b
expression after cryopreservation 
46. They proposed that
decreased antigen expression could be associated with
GPIb/CD42b proteolysis, mediated by calcium–activated
protease, or calpain.
It is generally accepted that the cold–induced
GP140/CD62p expression less than  40% could be an ade-
quate threshold, because higher expression values of
GP140/CD62p have been shown to result in platelet in vivo
recovery of less than 50% 
48). As shown in Table 3, freezing
promoted a raise in the number of platelets expressing
GP140/CD62p antigen. The percentage of platelets express-
ing GP140/CD62p in the controlled–rate group was signifi-
cantly lower than in the uncontrolled–rate sample. The ele-
vated GP140/CD62p values for cryopreserved cells pointed
to the platelet activation during the freezing/thawing proce-
dure.
The expression of GP140/CD62p was associated with the
clearance of platelets by the reticuloendothelial system 
48. More
than 50% of platelets stored at 22 °C expressed GP140/CD62p
on their surface after 5 days, which indicated that the cryopre-
served cells had the superior retention of intact granules, which
correlated with their in vivo functionality 
49. With respect to
GP53/CD63 antigen (activation marker of the externalization
of the contents from lysosomes), a considerable increase in
the expression of this antigen after freezing–thawing process
was observed. However, this increase in the GP53/CD63 ex-
pression was not as high as for GP140/CD62p antigen. This
finding might reflect the more intensive activator stimulus
necessary for the release of lysosomes compared to that of
α–granules 
50.
In this study, the GPIIb–IIIa/CD41 (the main platelet
aggregation protein) examination showed the decrease in
cryopreserved platelets in both groups. However, the reduc-
tion of GPIIb–IIIa/CD41 was not significant after con-
trolled–rate freezing vs. the control group (opposite to un-
controlled–rate freezing), which is in agreement with data
from the literature 
51, 52. GPIV/CD36 is an accelerator of the
interaction between platelets and collagen and it is a media-
tor of the platelet adhesion to subendothelial surfaces 
53.
Cryopreserved platelets in the present investigation obtained
a significant reduction of the expression of GPIV/CD36 as
compared to unfrozen platelets, but without intergroup dif-
ferences. These data are in accordance with data from the lit-
erature 
44.
For a successful cryopreservation not only the use of
appropriate freezing strategy, but also the selection of a
cryoprotectant in the optimized concentration is required.
For platelet and lymphocyte freezing, DMSO and/or hy-
droxyethyl starch (HES) dissolved in a cell–specific
“freezing medium” is commonly used, but with different
concentrations of cryoprotectant 
54, 55. In the present study,
6% DMSO in autologous plasma (platelet setting), and 10%
DMSO in RPMI 1640 (lymphocyte setting) were used. Our
earlier cryoinvestigation showed that the TNC and the
committed progenitor recovery was better when the lower
(5%) DMSO and controlled–rate freezing were used. In
contrast, pluripotent Makrow Repopulating Ability (MRA)
cells could only be well cryopreserved in the presence of
10% DMSO 
10. These data implied a different “cryobi-
ological request” of MRA cells in comparison to the com-
mitted progenitors or TNCs. However, as recently pre-
sented, the postthaw cell quality is better when rHu–DNase,
membrane stabilizers or bioantioxidants are added to the
Conventional Freezing Medium (CFM) 
56–58. Accordingly,
it is possible that the use of these additives is more success-
ful than the reduction of DMSO concentration. We also
showed that the differences in the cell recovery and func-
tionality rates were not related to the changes in the total
number of frozen/thawed cells 
10, 11.
In this research, the obtained lymphocyte recovery was
significantly better in the controlled–rate vs. uncontrolled–
rate settings. These results are in agreement with our earlier
findings for TNCs and lymphocytes 
11, 35, and they are also in
accordance with the data from other authors 
36, 37, 59. On the other
hand, we obtained no significant differences in mitogen induced
proliferation of lymphocytes after the controlled–rate vs. uncon-
trolled–rate procedure. Proliferative response to mitogens or mi-
crobial antigens is often used as a measure of lymphocyte func-
tionality. Weinberg et al. 
60 showed that the results of functional
assays on cryopreserved peripheral blood MNCs are associated
with cell viability. Although the obtained TBNCR values were
markedly higher in the controlled–rate group, the proportion
of viable cells was high (≈ 90%) for both procedures (Table 1)
which can explain a similar proliferative response of lymphocytes
after different freezing methods.Volumen 63, N
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Conclusion
In conclusion, the results presented here point undoubt-
edly out the controlled–rate system (with the compensated
fusion heat) which resulted in a superior platelet recovery of
the tested parameters. A simultaneous analysis of platelet
surface antigens and cell micro–integrity markers could pre-
dict certain in vivo properties of the cooled, especially cryo-
preserved platelets, however these postulates should be con-
firmed. The lymphocyte recovery and TBNCR values were
obviously lower in the uncontrolled–rate setting. The ob-
tained high–level postthaw cell viability can explain their
similar proliferative response regardless the used freezing.
Further researches in various blood–derived cell settings are
recommended to define the optimal cell–specific cryopreser-
vation strategy with the best cell recovery.
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